How did RDHL's revenue and expenses trend in Q2 2023?

Redhill Biopharma (RDHL) experienced a decline in revenue and a reduction in operating expenses in Q2 2023 compared to the previous quarter.

1. **Revenue Trend**: The revenue by business for RDHL in Q2 2023 was $6.53 million, which represents a decrease of 7.88% from the previous quarter's revenue of $5.58 million. Additionally, there was a negative revenue of $182,000 from Movantik, a business segment.

2. **Cost and Expense Trend**: The cost of goods sold (COGS) for RDHL in Q2 2023 was $806,000, which is the same as the previous quarter's COGS. However, the operating expenses were $0 in Q2 2023, compared to the previous quarter's operating expenses, which were not provided.

In summary, RDHL's revenue declined in Q2 2023, while the company's operating expenses were reduced compared to the previous quarter.